Victoria C.
Legal
Victoria Cladwell is a legal author with a Bachelor of Arts in Political Science from the University of North Carolina at Chapel Hill. For more than ten years, she has researched and written on U.S. law, covering topics such as consumer rights, employment law, civil litigation, personal injury, and legal procedures.
Before becoming an independent legal author, Victoria worked in legal content and editorial roles at Thomson Reuters and LexisNexis, where she contributed to legal research materials, practice guides, and public-facing legal publications. Today, she focuses on creating clear, accurate, and well-researched legal content that helps readers better understand the U.S. legal system.
Email: victoria.c@mavengity.com
Top 6 articles by Victoria C.
Fauci Pleaded the Fifth. To Take That Right Away, Rand Paul Would Have to Give Up His Case.
Fauci declined to answer questions under subpoena, invoking the Fifth Amendment for what appears to be the first time in more than 250 congressional appearances. Paul's new theory, that a pardon might strip that right, contradicts the very premise that made the hearing worth holding.
The FTC's Case Against Hims Looks Like Three Complaints. It's Really One Business Model.
The FTC alleges Hims shared health data with Meta and Snap, billed patients almost immediately after intake, and made subscriptions hard to cancel. Each is the direct-to-consumer growth playbook, frictionless conversion, sticky subscriptions, pixel-based ad targeting, colliding with a part of healthcare law it doesn't account for.
Rand Paul Wants Two Things From Fauci's Testimony. They Work Against Each Other.
Wednesday's subpoenaed hearing is framed as both a fact-finding inquiry into COVID's origins and a path toward a perjury charge. The second goal gives Fauci every reason to say as little as possible, which defeats the first. The structure, not the politics, explains what the hearing will produce.
The New Student Visa Rule Sets a Four-Year Clock. A PhD Takes Five to Six. That Gap Is the Whole Problem.
DHS replaced open-ended student status with a fixed four-year term and a discretionary extension. Most US doctorates take longer than that, which routes nearly every foreign PhD student and many postdocs through a legal checkpoint in the middle of long, stability-dependent research.
An Outright Ban on Drug Ads Would Probably Lose in Court. The Rule the FDA Is Already Writing Might Not.
Public Citizen petitioned the FDA to ban direct-to-consumer drug advertising outright. The agency is already pursuing a disclosure rule that could reach a similar result while surviving First Amendment review the ban likely would not.
Novo Sued Lilly Over GLP-1 Ads. Lilly's Defense Is Better Than It Sounds.
The allegation is that Lilly compares its highest doses against Novo's lower ones, omitting a Wegovy dose the FDA approved in March. Lilly's answer is that it cites the only head-to-head trial that exists between the two drugs. Both claims are accurate, and the conflict between them is a structural problem that will keep producing lawsuits.